Dr Sam Gillard Duncan, RPH is a
Pharmacist based in Ritzville, Washington. Dr Sam Gillard Duncan is licensed to practice in Washington (license number PH00015721) and his current practice location is
209 W. Main Ave, Ritzville Drug Company, Ritzville, Washington. He can be reached at his office (for appointments etc.) via phone at
(509) 659-0250.
NPI number for Dr Sam Gillard Duncan is 1689739583 and his current mailing address is 3804 Moscow Mountain Rd, Moscow, Idaho. He
does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1689739583.
Healthcare Provider's Profile
Full Name | Dr Sam Gillard Duncan |
---|
Gender | Male |
---|
Speciality | Pharmacist |
---|
Location | 209 W. Main Ave, Ritzville, Washington |
---|
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
NPI Data:
- NPI Number: 1689739583
- Provider Enumeration Date: 12/22/2006
- Last Update Date: 07/09/2007
Medical Identifiers
Medical identifiers for Dr Sam Gillard Duncan such as npi, medicare ID, medicare PIN, medicaid, etc.
Identifier | Type | State | Issuer |
1689739583 | NPI | - | NPPES |
6093603 | Medicaid | WA | |
Medical Taxonomies and Licenses
Taxonomy | Type | License (State) | Status |
183500000X | Pharmacist | PH00015721 (Washington) | Primary |
Medicare Part D Prescriber Enrollment
Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Sam Gillard Duncan is
NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.
Mailing Address and Practice Location
Mailing Address | Practice Location Address |
Dr Sam Gillard Duncan, RPH 3804 Moscow Mountain Rd, Moscow, ID 83843-8113 Ph: (208) 883-7632 | Dr Sam Gillard Duncan, RPH 209 W. Main Ave, Ritzville Drug Company, Ritzville, WA 99169 Ph: (509) 659-0250 |
Reviews and Comments